Novo Nordisk invests $380M to expand manufacturing in Czech Republic and China, while Cellares raises $50M Series D
Novo Nordisk announced a significant investment to broaden its manufacturing footprint in both China and the Czech Republic.
In the Czech Republic, the company is allocating roughly $380 million to enlarge its plant in Bohumil, Central Bohemia, aiming to boost production capacity.
In China, Novo Nordisk is also expanding its facilities, though the specific financial commitment was not disclosed in the brief.
Meanwhile, biotech Cellares secured an additional $50 million in its Series D financing round, strengthening its capital base for ongoing development.
The announcements reflect continued growth activity in the pharmaceutical sector, with companies seeking to scale production and fund innovation.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that